These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. Role of the microenvironment in tumor growth and in refractoriness/resistance to anti-angiogenic therapies. Shojaei F; Ferrara N Drug Resist Updat; 2008 Dec; 11(6):219-30. PubMed ID: 18948057 [TBL] [Abstract][Full Text] [Related]
43. Growing tumor vessels: more than one way to skin a cat - implications for angiogenesis targeted cancer therapies. Leite de Oliveira R; Hamm A; Mazzone M Mol Aspects Med; 2011 Apr; 32(2):71-87. PubMed ID: 21540050 [TBL] [Abstract][Full Text] [Related]
44. Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases. Carmeliet P; Jain RK Nat Rev Drug Discov; 2011 Jun; 10(6):417-27. PubMed ID: 21629292 [TBL] [Abstract][Full Text] [Related]
49. Potential Role of Natural Compounds as Anti-Angiogenic Agents in Cancer. Shanmugam MK; Warrier S; Kumar AP; Sethi G; Arfuso F Curr Vasc Pharmacol; 2017; 15(6):503-519. PubMed ID: 28707601 [TBL] [Abstract][Full Text] [Related]
50. Angiogenesis as a target for breast cancer therapy. Rayson D; Vantyghem SA; Chambers AF J Mammary Gland Biol Neoplasia; 1999 Oct; 4(4):415-23. PubMed ID: 10705924 [TBL] [Abstract][Full Text] [Related]
51. Clinical implications of angiogenesis in cancers. Pang RW; Poon RT Vasc Health Risk Manag; 2006; 2(2):97-108. PubMed ID: 17319453 [TBL] [Abstract][Full Text] [Related]
52. Sigma receptor-mediated targeted delivery of anti-angiogenic multifunctional nanodrugs for combination tumor therapy. Li Y; Wu Y; Huang L; Miao L; Zhou J; Satterlee AB; Yao J J Control Release; 2016 Apr; 228():107-119. PubMed ID: 26941036 [TBL] [Abstract][Full Text] [Related]
53. Is copper chelation an effective anti-angiogenic strategy for cancer treatment? Antoniades V; Sioga A; Dietrich EM; Meditskou S; Ekonomou L; Antoniades K Med Hypotheses; 2013 Dec; 81(6):1159-63. PubMed ID: 24210000 [TBL] [Abstract][Full Text] [Related]
54. Vascular targeting therapy: potential benefit depends on tumor and host related effects. Horsman MR; Bohn AB; Busk M Exp Oncol; 2010 Sep; 32(3):143-8. PubMed ID: 21403608 [TBL] [Abstract][Full Text] [Related]
55. [Tumor angiogenesis: new approaches to cancer therapy]. Marmé D Onkologie; 2001 Feb; 24 Suppl 1():1-5. PubMed ID: 11441305 [TBL] [Abstract][Full Text] [Related]
56. The potential of fibroblast growth factor/fibroblast growth factor receptor signaling as a therapeutic target in tumor angiogenesis. Ronca R; Giacomini A; Rusnati M; Presta M Expert Opin Ther Targets; 2015; 19(10):1361-77. PubMed ID: 26125971 [TBL] [Abstract][Full Text] [Related]
57. Metabolic effects of antiangiogenic drugs in tumors: therapeutic implications. Quintieri L; Selmy M; Indraccolo S Biochem Pharmacol; 2014 May; 89(2):162-70. PubMed ID: 24607274 [TBL] [Abstract][Full Text] [Related]
58. Biology of vascular endothelial growth factor and its receptors in head and neck cancer: beyond angiogenesis. Christopoulos A; Ahn SM; Klein JD; Kim S Head Neck; 2011 Aug; 33(8):1220-9. PubMed ID: 21755565 [TBL] [Abstract][Full Text] [Related]
59. Novel endogenous angiogenesis inhibitors and their therapeutic potential. Rao N; Lee YF; Ge R Acta Pharmacol Sin; 2015 Oct; 36(10):1177-90. PubMed ID: 26364800 [TBL] [Abstract][Full Text] [Related]
60. Vascular endothelial growth factor receptor as target for advanced non-small cell lung cancer therapy. Rossi A; Maione P; Sacco PC; Ambrosio R; Falanga M; Gridelli C Curr Drug Targets; 2010 Jul; 11(7):865-8784. PubMed ID: 20412044 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]